NewEdge Advisors
TLX icon

NewEdge Advisors’s Telix Pharmaceuticals TLX Stock Holding History

NewEdge Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.1K Hold
1,920
– – ﹤0.01% 3333
2026
Q1 		$18.4K Hold
1,920
– – ﹤0.01% 3219
2025
Q4 		$14.4K Sell
1,920
-480
-20% -$4.62K ﹤0.01% 3356
2025
Q3 		$23K Buy
+2,400
New +$29.4K ﹤0.01% 3081

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
Portland Investment Counsel
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Integrated Wealth Concepts
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

NewEdge Advisors's TLX Position: Q2 2026 in Review

NewEdge Advisors held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 1,920 shares worth $22.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3333.

NewEdge Advisors first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. The position peaked at $23K in Q3 2025. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • NewEdge Advisors held 1,920 shares of Telix Pharmaceuticals worth $22.1K as of Q2 2026.
  • NewEdge Advisors left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3333 holding.
  • NewEdge Advisors first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • NewEdge Advisors's Telix Pharmaceuticals position peaked at $23K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.